Published in Bull World Health Organ on January 01, 1971
Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol (2003) 2.91
Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun (2001) 2.86
The meningococcus and mechanisms of pathogenicity. Microbiol Rev (1982) 2.39
Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest (1975) 2.16
A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria. Bull World Health Organ (1977) 1.87
Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis (2003) 1.81
Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev (2006) 1.53
Meningococcal infections. 3. Studies of group A polysaccharide vaccines. Bull World Health Organ (1971) 1.23
Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Clin Diagn Lab Immunol (2004) 1.22
Antibody responses to meningococcal polysaccharide vaccines. Infect Immun (1973) 1.11
Development of a Neisseria meningitidis group B serotype 2b protein vaccine and evaluation in a mouse model. Infect Immun (1984) 1.11
Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease. Microbiol Mol Biol Rev (2013) 1.05
Meningitis in the central Arctic: a 4-year experience. Can Med Assoc J (1981) 1.04
Activation of murine B lymphocytes by Neisseria meningitidis and isolated meningococcal surface antigens. Infect Immun (1983) 1.00
Group C Neisseria meningitidis variant polysaccharide vaccines in children. Infect Immun (1981) 0.97
Will there ever be a universal Staphylococcus aureus vaccine? Hum Vaccin Immunother (2013) 0.97
Dynamics of acute bacterial diseases. Epidemiological models and their application in public health. Part II. Epidemiological models of acute bacterial diseases. Bull World Health Organ (1978) 0.95
Comparison of passive hemagglutination, bactericidal activity, and radioimmunological methods in measuring antibody responses to Neisseria meningitidis group A capsular polysaccharide vaccine. J Clin Microbiol (1980) 0.95
Three cases of meningococcal infection in a family, associated with a deficient immune response. Arch Dis Child (1973) 0.94
Impact of a mass immunization campaign against serogroup C meningococcus in the Province of Quebec, Canada. Bull World Health Organ (1996) 0.93
Global practices of meningococcal vaccine use and impact on invasive disease. Pathog Glob Health (2014) 0.91
Immunological and biochemical studies of meningococcal C polysaccharides isolated by diethylaminoethyl chromatography. Infect Immun (1976) 0.91
Meningococcal conjugate vaccines: optimizing global impact. Infect Drug Resist (2011) 0.89
Human opsonins to meningococci after vaccination. Infect Immun (1984) 0.88
Meningococcal group C conjugate vaccines. Arch Dis Child (2001) 0.86
Dramatic decline of serogroup C meningococcal disease incidence in Catalonia (Spain) 24 months after a mass vaccination programme of children and young people. J Epidemiol Community Health (2001) 0.83
Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda. PLoS Negl Trop Dis (2008) 0.82
Immunogenicity and side-effects of a new tetravalent meningococcal polysaccharide vaccine. Bull World Health Organ (1983) 0.80
Meningococcal disease serogroup C. Risk Manag Healthc Policy (2012) 0.79
How the Knowledge of Interactions between Meningococcus and the Human Immune System Has Been Used to Prepare Effective Neisseria meningitidis Vaccines. J Immunol Res (2015) 0.77
Surveillance of meningococcal infections and other forms of purulent meningitis: a 4-year study in the USSR. Bull World Health Organ (1986) 0.76
Should university students be vaccinated against meningococcal disease in Canada? Can J Infect Dis (2004) 0.75
Prospects for new vaccines. Postgrad Med J (1976) 0.75
Editorial: Vaccination against meningitis. Br Med J (1976) 0.75
Duration of the immune response in subjects inoculated with antimeningococcal A and C vaccines kept in storage at -20 degrees C and at 4 degrees C: influence of pre-vaccination titres on the vaccinal response. J Hyg (Lond) (1981) 0.75
Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides. J Exp Med (1969) 8.30
Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med (1969) 6.17
Serological typing of meningococci by means of micro-precipitation. Antonie Van Leeuwenhoek (1961) 5.41
Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med (1970) 4.90
Prevalence of meningococcal serogroups and description of three new groups. Am J Epidemiol (1968) 4.34
Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. J Exp Med (1969) 3.96
Cutaneous reactions and antibody response to meningococcal group C polysaccharide vaccines in man. J Infect Dis (1970) 2.71
Meningococcal infections. 1. Prevalence of serogroups causing disease in US Army personnel in 1964-70. Bull World Health Organ (1971) 1.50
Evaluation of group C meningococcal polysaccharide vaccine in marine recruits, San Diego, California. Am J Epidemiol (1970) 1.34
Respiratory disease and the adenoviruses. Med Clin North Am (1967) 1.11
Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med (1969) 13.87
Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr (1984) 9.61
Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med (1969) 9.01
Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides. J Exp Med (1969) 8.30
Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med (1969) 6.17
Development of a short 'readiness to change' questionnaire for use in brief, opportunistic interventions among excessive drinkers. Br J Addict (1992) 5.02
Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med (1970) 4.90
Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis (1972) 4.54
Immunochemical similarity between polysaccharide antigens of Escherichia coli 07: K1(L):NM and group B Neisseria meningitidis. J Immunol (1973) 4.49
Prevalence of meningococcal serogroups and description of three new groups. Am J Epidemiol (1968) 4.34
Analysis of parameters affecting the solid phase radioimmunoassay quantitation of antibody to meningococcal antigens. J Immunol (1976) 4.02
Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J Infect Dis (1978) 4.00
Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. J Exp Med (1969) 3.96
Neisseria gonorrhoeae and neisseria meningitidis: extracellular enzyme cleaves human immunoglobulin A. Science (1975) 3.27
Congenital rubella. Clinicopathologic, virologic, and immunologic studies. Am J Dis Child (1965) 2.82
Cutaneous reactions and antibody response to meningococcal group C polysaccharide vaccines in man. J Infect Dis (1970) 2.71
Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology (2012) 2.60
Serologic studies of meningococcal infection and polysaccharide vaccination. J Infect Dis (1971) 2.54
Antigenic specificity of bactericidal antibodies in antisera to Neisseria meningitidis. J Infect Dis (1973) 2.47
The pathology of the joint tissues and its clinical relevance in prosthesis failure. Clin Orthop Relat Res (1976) 2.46
Disseminated fusarial infection in the immunocompromised host. Rev Infect Dis (1989) 2.46
Isolation and characterization of a native cell wall complex from Neisseria meningitidis. Infect Immun (1972) 2.43
Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr (1990) 2.28
2.5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy. Lancet (1997) 2.28
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology (2011) 2.26
Cross-reactivity of Neisseria gonorrhoeae and Neisseria meningitidis and the nature of antigens involved in the bactericidal reaction. J Infect Dis (1974) 2.24
Adverse reactions to diphtheria, tetanus, pertussis-polio vaccination at 18 months of age: effect of injection site and needle length. Pediatrics (1989) 2.21
Acetaminophen prophylaxis of adverse reactions following vaccination of infants with diphtheria-pertussis-tetanus toxoids-polio vaccine. Pediatr Infect Dis J (1987) 2.20
Identification of an epidemic strain of group C Neisseria meningitidis by bactericidal serotyping. J Infect Dis (1971) 2.17
Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest (1975) 2.16
Results from the 1995 National College Health Risk Behavior Survey. J Am Coll Health (1997) 2.13
Herpesvirus infections of the human central nervous system. N Engl J Med (1967) 2.09
Human antibody response to three meningococcal outer membrane antigens: comparison by specific hemagglutination assays. Infect Immun (1974) 2.00
[Fumaric acid as therapeutic agent for multiple sclerosis]. Nervenarzt (2014) 1.97
Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis. Brain (2001) 1.91
Safety and immunogenicity of a Neisseria meningitidis type 2 protein vaccine in animals and humans. J Infect Dis (1978) 1.86
Etiology of acute childhood encephalitis at The Hospital for Sick Children, Toronto, 1994-1995. Clin Infect Dis (1998) 1.85
Aerosol stability of three acute respiratory disease viruses. Proc Soc Exp Biol Med (1967) 1.84
Acute respiratory disease and meningococcal infection in army recruits. JAMA (1967) 1.73
Survey of parents' attitudes to the recommended Haemophilus influenzae type b vaccine program. CMAJ (1987) 1.72
Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis (1979) 1.67
Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol (2006) 1.62
Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia. J Antimicrob Chemother (1983) 1.60
A radioactive antigen-binding assay for Neisseria meningitidis polysaccharide antibody. J Immunol (1972) 1.54
Immunoepidemiology of meningococcal disease in military recruits. I. A model for serogroup independency of epidemic potential as determined by serotyping. J Infect Dis (1977) 1.54
Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics (1977) 1.50
Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis. Evidence for programmed cell death as a mechanism to control inflammation in the brain. Am J Pathol (1993) 1.50
Meningococcal infections. 1. Prevalence of serogroups causing disease in US Army personnel in 1964-70. Bull World Health Organ (1971) 1.50
Antibody-dependent cell-mediated antibacterial activity of human mononuclear cells. I. K lymphocytes and monocytes are effective against meningococi in cooperation with human imune sera. J Exp Med (1979) 1.49
Superficial siderosis of the central nervous system: pathogenetic heterogeneity and therapeutic approaches. Acta Neurol Scand (2003) 1.49
Air sampling for respiratory disease agents in army recruits. Bacteriol Rev (1966) 1.48
Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol (2008) 1.46
["Chronic cerebrospinal venous insufficiency" and multiple sclerosis: critical analysis and first observation in an unselected cohort of MS patients]. Nervenarzt (2010) 1.45
A new histologic approach to the differentiation of enchondroma and chondrosarcoma of the bones. A clinicopathologic analysis of 51 cases. Clin Orthop Relat Res (1985) 1.42
Treating HIV encephalopathy with antiretroviral therapy: a clinical case demonstrating the success of HAART. Clin Infect Dis (2004) 1.41
Intravenous Immunoglobulins in MS. Int MS J (2005) 1.41
Chronic recurrent multifocal osteomyelitis: a noninfectious inflammatory process. Pediatr Infect Dis J (1987) 1.37
Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. Blood (2000) 1.35
Giant axonal neuropathy. A clinically and morphologically distinct neurological disease. Arch Neurol (1974) 1.34
Antibody responses in serum and nasal secretions of children immunized with inactivated and attenuated measles-virus vaccines. N Engl J Med (1969) 1.32
Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol (1989) 1.31
A specific circulating antigen in hamsters infected with Schistosoma mansoni. Detection of antigen in serum and urine, and correlation between antigenic concentration and worm burden. Am J Trop Med Hyg (1969) 1.30
The sequelae of Haemophilus influenzae meningitis in school-age children. N Engl J Med (1990) 1.27
The Immunization Monitoring Program Active (IMPACT) prospective five year study of Canadian children hospitalized for chickenpox or an associated complication. Pediatr Infect Dis J (2000) 1.27
Meningococcal infections. 3. Studies of group A polysaccharide vaccines. Bull World Health Organ (1971) 1.23
Latex agglutination test for measurement of antibodies to meningococcal polysaccharides. Infect Immun (1972) 1.21
Adenoviral pneumonia and its complications in infancy and childhood. J Can Assoc Radiol (1969) 1.20
Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis. Pediatr Infect Dis (1985) 1.19
Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology (2004) 1.19
Microglial phagocytosis of apoptotic inflammatory T cells leads to down-regulation of microglial immune activation. J Immunol (2001) 1.18
Sequelae of acute bacterial meningitis in children treated for seven days. Pediatrics (1986) 1.17
Systemic lysostaphin in man--apparent antimicrobial activity in a neutropenic patient. N Engl J Med (1974) 1.16
Fumaric Acid and its esters: an emerging treatment for multiple sclerosis. Curr Neuropharmacol (2009) 1.15
Large-volume air sampling for Meningococci and Adenoviruses. Am J Epidemiol (1968) 1.14
Diffusion of ions in myelinated nerve fibers. Biophys J (1979) 1.14
Immune Response of human infants of polysaccharide vaccines of group A and C Neisseria meningitidis. J Infect Dis (1977) 1.13
Response of children to Neisseria meningitidis polysaccharide vaccines. J Infect Dis (1973) 1.13
Clinical correlation of strain differentiation of Neisseria gonorrhoeae. J Infect Dis (1976) 1.13
Administration of measles, mumps, and rubella virus vaccine (live) to egg-allergic children. JAMA (1990) 1.12
Epidemiologic study of 4684 hospital-acquired infections in pediatric patients. Pediatr Infect Dis J (1989) 1.12
Antibody responses to meningococcal polysaccharide vaccines. Infect Immun (1973) 1.11
High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch Neurol (2001) 1.10
Meningococcal infections. 5. Duration of polysaccharide-vaccine-induced antibody. Bull World Health Organ (1971) 1.10
Prophylaxis for meningococcal disease. JAMA (1975) 1.09
Large-volume air sampling of human respiratory disease pathogens. Am J Epidemiol (1967) 1.09
Clinical and epidemiological correlates of Pseudomonas typing. J Infect Dis (1974) 1.09
Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin. J Pediatr (1982) 1.09
[Treatment of relapsing-remitting multiple sclerosis with recombinant interferon-beta preparations]. Nervenarzt (2001) 1.08
Gene transfer through the blood-nerve barrier: NGF-engineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis. Nat Med (1995) 1.08
Analysis of the mouse gamma-crystallin gene family: assignment of multiple cDNAs to discrete genomic sequences and characterization of a representative gene. Nucleic Acids Res (1984) 1.08
Attempted prophylaxis against meningococcal infection using intramuscular penicillin. Mil Med (1967) 1.08
Adult meningoencephalitis caused by herpesvirus hominis type 2. Am J Med (1974) 1.08
Diagnostic accuracy of CT angiography and CT perfusion for cerebral vasospasm: a meta-analysis. AJNR Am J Neuroradiol (2010) 1.08
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Mult Scler (2010) 1.07